Physician profile
Steven Mattleman
NPI 1902809866
$4,230.84
in general payments reported to CMS, 2019-2025
30 companies · $835 in 2025
The $835 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $961 · 2020: $309 · 2021: $145 · 2022: $476 · 2023: $581 · 2024: $924 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,340.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $876.52 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $498.93 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $343.97 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $298.05 | 2019-2023 | Watchman Access System |
| Amgen INC. | $276.73 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $241.18 | 2020-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $206.52 | 2019-2025 | Farxiga, Wainua |
| Novo Nordisk INC | $166.73 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Philips North America LLC | $157.16 | 2020-2025 | (Ck4) Mcot, Extended Holter, Holter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $156.43 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $140.28 | 2023-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $138.47 | 2019-2024 | |
| Kestra Medical Technology Services, INC. | $107.51 | 2024-2025 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $101.16 | 2023-2025 | Onpattro, Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.34 | 2019-2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $71.69 | 2019-2023 | |
| Astellas Pharma US INC | $58.09 | 2019-2022 | |
| Abbott Laboratories | $49.24 | 2022-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Lexicon Pharmaceuticals, INC. | $43.47 | 2023-2024 | Inpefa |
| Ge Healthcare | $24.19 | 2023 | |
| Baxter Healthcare | $23.55 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Lilly USA, LLC | $21.53 | 2025 | Mounjaro |
| Daiichi Sankyo INC. | $21.52 | 2019 | |
| Braemar Manufacturing, LLC | $18.61 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $17.83 | 2024 | Arcalyst |
| Althera Pharmaceuticals LLC | $17.62 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $17.37 | 2023 | Arcalyst |
| Edwards Lifesciences Corporation | $16.94 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Regeneron Healthcare Solutions, INC. | $13.94 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Mattleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.